Affordable Access

Publisher Website

Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.

Authors
Type
Published Article
Journal
Expert Opinion on Pharmacotherapy
1744-7666
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
11
Issue
12
Pages
2077–2085
Identifiers
DOI: 10.1517/14656566.2010.499358
PMID: 20642373
Source
Medline

Abstract

Indacaterol is a new, once-daily beta(2)-agonist with an onset of action within 5 min and a duration of bronchodilation of at least 24 h. In doses of 150 and 300 microg, it has sustained benefits over 6 - 12 months with respect to both bronchodilation and patient-reported outcomes and is well-tolerated with an acceptable safety profile.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments